MY175854A - Novel quinolone derivatives - Google Patents

Novel quinolone derivatives

Info

Publication number
MY175854A
MY175854A MYPI2015001457A MYPI2015001457A MY175854A MY 175854 A MY175854 A MY 175854A MY PI2015001457 A MYPI2015001457 A MY PI2015001457A MY PI2015001457 A MYPI2015001457 A MY PI2015001457A MY 175854 A MY175854 A MY 175854A
Authority
MY
Malaysia
Prior art keywords
quinolone derivatives
novel quinolone
preparation
novel
compounds
Prior art date
Application number
MYPI2015001457A
Other languages
English (en)
Inventor
Ranjit C Desai
Pankaj Patel
Vrajesh Pandya
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54148255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY175854(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of MY175854A publication Critical patent/MY175854A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60N-oxides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Quinoline Compounds (AREA)
MYPI2015001457A 2012-12-24 2013-12-23 Novel quinolone derivatives MY175854A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3600MU2012 2012-12-24

Publications (1)

Publication Number Publication Date
MY175854A true MY175854A (en) 2020-07-14

Family

ID=54148255

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2015001457A MY175854A (en) 2012-12-24 2013-12-23 Novel quinolone derivatives

Country Status (26)

Country Link
US (1) US9394300B2 (cg-RX-API-DMAC10.html)
EP (1) EP2935221B1 (cg-RX-API-DMAC10.html)
JP (1) JP6026013B2 (cg-RX-API-DMAC10.html)
KR (1) KR101733901B1 (cg-RX-API-DMAC10.html)
CN (1) CN104903295B (cg-RX-API-DMAC10.html)
AP (1) AP2015008502A0 (cg-RX-API-DMAC10.html)
AR (1) AR094300A1 (cg-RX-API-DMAC10.html)
AU (1) AU2013368843B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015014222B1 (cg-RX-API-DMAC10.html)
CA (1) CA2894636C (cg-RX-API-DMAC10.html)
CL (1) CL2015001802A1 (cg-RX-API-DMAC10.html)
EA (1) EA028402B1 (cg-RX-API-DMAC10.html)
ES (1) ES2660288T3 (cg-RX-API-DMAC10.html)
IL (1) IL239109B (cg-RX-API-DMAC10.html)
JO (1) JO3781B1 (cg-RX-API-DMAC10.html)
MA (1) MA38138A1 (cg-RX-API-DMAC10.html)
MX (1) MX373392B (cg-RX-API-DMAC10.html)
MY (1) MY175854A (cg-RX-API-DMAC10.html)
NZ (1) NZ708605A (cg-RX-API-DMAC10.html)
PH (1) PH12015501452B1 (cg-RX-API-DMAC10.html)
SG (1) SG11201504458XA (cg-RX-API-DMAC10.html)
TR (1) TR201802305T4 (cg-RX-API-DMAC10.html)
TW (1) TWI598339B (cg-RX-API-DMAC10.html)
UA (1) UA117122C2 (cg-RX-API-DMAC10.html)
WO (1) WO2014102818A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201503814B (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016034108A1 (zh) * 2014-09-02 2016-03-10 广东东阳光药业有限公司 喹啉酮类化合物及其应用
WO2016045125A1 (en) * 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibitors of hif prolyl hydroxylase
CL2015003047A1 (es) * 2015-10-15 2016-06-17 Univ Chile Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
CN108069957B (zh) * 2016-11-09 2022-11-04 广东东阳光药业有限公司 脯氨酰羟化酶抑制剂及其用途
ES2934361T3 (es) 2017-05-09 2023-02-21 Kind Pharmaceutical Derivados de indolizina y aplicación de los mismos en medicina
CA3091142C (en) 2018-02-26 2023-04-11 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
WO2021181360A1 (en) * 2020-03-13 2021-09-16 Cadila Healthcare Limited Novel salts of quinolone compounds
EP4121009A4 (en) * 2020-03-17 2024-04-17 Zydus Lifesciences Limited Formulation comprising hif prolyl hydroxylase inhibitors
TW202200134A (zh) 2020-04-20 2022-01-01 美商阿克比治療有限公司 治療病毒感染、器官損傷及相關症狀之方法
WO2021240454A1 (en) * 2020-05-29 2021-12-02 Cadila Healthcare Limited Treatment for psoriasis and skin inflammatory diseases
WO2021245533A1 (en) * 2020-06-01 2021-12-09 Cadila Healthcare Limited Treatment for the inflammatory bowel disease
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
KR20230159487A (ko) * 2021-03-19 2023-11-21 자이두스 라이프사이언시즈 리미티드 고체 형태의 퀴놀론 화합물 및 이의 제조 방법
WO2022195532A1 (en) * 2021-03-19 2022-09-22 Zydus Lifesciences Ltd. Treatment for sickle cell anaemia
WO2022238745A1 (en) * 2021-05-14 2022-11-17 Zydus Lifesciences Limited Topical pharmaceutical composition of hif prolyl hydroxylase inhibitors
EP4347022A1 (en) 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate
CN113549011B (zh) * 2021-08-10 2023-05-09 广东东阳光药业有限公司 德度司他的共晶或盐及其制备方法和用途
EP4405335A4 (en) * 2021-09-20 2025-08-06 Zydus Lifesciences Ltd DESIDUSTAT PARTICLES AND THEIR COMPOSITIONS
US20250387385A1 (en) * 2022-06-24 2025-12-25 Zydus Lifesciences Limited Treatment for glomerular diseases
EP4565233A1 (en) * 2022-08-01 2025-06-11 Zydus Lifesciences Limited Treatment for aplastic anemia (aa)

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW406076B (en) 1993-12-30 2000-09-21 Hoechst Ag Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
CA2528232C (en) 2003-06-06 2010-05-25 Fibrogen, Inc. Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
US8703795B2 (en) * 2005-03-02 2014-04-22 Fibrogen, Inc. Thienopyridine compounds, and methods of use thereof
WO2007038571A2 (en) * 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
JP5202327B2 (ja) 2005-12-09 2013-06-05 アムジエン・インコーポレーテツド プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用
AR059733A1 (es) * 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
KR101084635B1 (ko) * 2006-04-04 2011-11-18 피브로겐, 인크. Hif 조절제로서 피롤로- 및 티아졸로-피리딘 화합물
WO2007136990A2 (en) * 2006-05-16 2007-11-29 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
AU2007275816A1 (en) * 2006-07-17 2008-01-24 Merck Sharp & Dohme Corp. 1-hydroxy naphthyridine compounds as anti-HIV agents
US8048892B2 (en) * 2006-12-18 2011-11-01 Amgen Inc. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
CA2683758A1 (en) * 2007-04-18 2008-10-30 Merck & Co., Inc. Novel 1,8-naphthyridine compounds
ES2442847T3 (es) * 2007-04-18 2014-02-13 Amgen, Inc Quinolonas y azaquinolonas que inhiben la prolil hidroxilasa
AU2008248165B2 (en) * 2007-05-04 2011-12-08 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
EP2150251B9 (en) * 2007-05-04 2013-02-27 Amgen, Inc Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
AU2008251031B2 (en) * 2007-05-16 2013-12-19 Norman Terry Cowper System and method for maximising solids concentration of slurry pumped through a pipeline
US20100305154A1 (en) * 2007-11-30 2010-12-02 Glaxosmithkline Llc Prolyl Hydroxylase Inhibitors
EP2257170B1 (en) * 2008-02-25 2012-12-26 Merck Sharp & Dohme Corp. Tetrahydrofuropyridones
AU2009217543A1 (en) * 2008-02-25 2009-09-03 Merck Sharp & Dohme Corp. Tetrahydro-1H-pyrrolo fused pyridones
JP2011513222A (ja) * 2008-02-25 2011-04-28 メルク・シャープ・エンド・ドーム・コーポレイション テトラヒドロチエノピリジン
WO2009158315A1 (en) * 2008-06-25 2009-12-30 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
KR101850661B1 (ko) 2009-07-17 2018-04-19 니뽄 다바코 산교 가부시키가이샤 트리아졸로피리딘 화합물, 그리고 그 프롤릴 수산화효소 저해제 및 에리트로포이에틴 생성 유도제로서의 작용
JP2013502399A (ja) * 2009-08-20 2013-01-24 ヴィフォール (インターナショナル) アクチェンゲゼルシャフト 新規なキノリン系ヘプシジン拮抗薬
WO2012106472A1 (en) 2011-02-02 2012-08-09 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase
EP2758058B1 (en) 2011-09-23 2017-04-26 Merck Sharp & Dohme Corp. Substituted pyrimidines
EP2810944A1 (en) * 2012-01-31 2014-12-10 Toyama Chemical Co., Ltd. Heterocyclic compound having anti-hiv activity

Also Published As

Publication number Publication date
AP2015008502A0 (en) 2015-06-30
ZA201503814B (en) 2016-05-25
PH12015501452B1 (en) 2018-06-06
MA38138A1 (fr) 2016-11-30
ES2660288T3 (es) 2018-03-21
IL239109A0 (en) 2015-07-30
BR112015014222A2 (pt) 2017-07-11
HK1211022A1 (en) 2016-05-13
AU2013368843A1 (en) 2015-06-18
WO2014102818A1 (en) 2014-07-03
CN104903295A (zh) 2015-09-09
US9394300B2 (en) 2016-07-19
EP2935221B1 (en) 2018-02-07
TW201441196A (zh) 2014-11-01
EA201591195A1 (ru) 2015-10-30
JO3781B1 (ar) 2021-01-31
IL239109B (en) 2019-07-31
TWI598339B (zh) 2017-09-11
US20150299193A1 (en) 2015-10-22
AU2013368843B2 (en) 2016-02-25
KR101733901B1 (ko) 2017-05-08
MX373392B (es) 2020-04-20
UA117122C2 (uk) 2018-06-25
JP6026013B2 (ja) 2016-11-16
AR094300A1 (es) 2015-07-22
PH12015501452A1 (en) 2015-09-21
EP2935221A1 (en) 2015-10-28
KR20150085535A (ko) 2015-07-23
TR201802305T4 (tr) 2018-03-21
BR112015014222B1 (pt) 2022-12-06
CL2015001802A1 (es) 2015-10-02
CA2894636C (en) 2018-04-03
EA028402B1 (ru) 2017-11-30
NZ708605A (en) 2016-07-29
CA2894636A1 (en) 2014-07-03
CN104903295B (zh) 2017-09-01
SG11201504458XA (en) 2015-07-30
MX2015008233A (es) 2015-09-29
JP2016503052A (ja) 2016-02-01

Similar Documents

Publication Publication Date Title
MY175854A (en) Novel quinolone derivatives
PH12014502040A1 (en) Heterocyclyl compounds
PH12016500885A1 (en) Novel heterocyclic compounds
IN2014MN02598A (cg-RX-API-DMAC10.html)
MD20140063A2 (ro) Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV
PH12012500622A1 (en) Compounds for the treatment of dyslipidemia and related diseases
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
GEP201706718B (en) Aryl and heteroaryl fused lactams
IN2014CN04530A (cg-RX-API-DMAC10.html)
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
GEP20176631B (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
PH12015501609A1 (en) Phenicol antibacterials
IN2015DN01119A (cg-RX-API-DMAC10.html)
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
PH12014501943A1 (en) Novel compounds for the treatment of dyslipidemia and related diseases
PH12013500671A1 (en) Novel gpr 119 agonists
IN2015DN02109A (cg-RX-API-DMAC10.html)
TN2014000077A1 (en) Pyridazinone compounds and their use as daao inhibitors
UA111851C2 (uk) Сполуки піридазинону та їх використання як інгібіторів daao